Published in Cancer Weekly, January 23rd, 2001
ILX-651 is a synthetic pentapeptide analog of dolastatin, with a mechanism of action that is analogous to taxanes (e.g., TAXOLR and TaxotereR). A tubulin interactive, anti-mitotic compound, ILX-651 appears to be active in taxane-resistant tumors in preclinical animal models in human breast carcinoma. It also appears to be active for a variety...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.